160 related articles for article (PubMed ID: 10417759)
1. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
Olivero M; Valente G; Bardelli A; Longati P; Ferrero N; Cracco C; Terrone C; Rocca-Rossetti S; Comoglio PM; Di Renzo MF
Int J Cancer; 1999 Aug; 82(5):640-3. PubMed ID: 10417759
[TBL] [Abstract][Full Text] [Related]
2. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
3. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
[TBL] [Abstract][Full Text] [Related]
4. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.
Schmidt LS; Nickerson ML; Angeloni D; Glenn GM; Walther MM; Albert PS; Warren MB; Choyke PL; Torres-Cabala CA; Merino MJ; Brunet J; Bérez V; Borràs J; Sesia G; Middelton L; Phillips JL; Stolle C; Zbar B; Pautler SE; Linehan WM
J Urol; 2004 Oct; 172(4 Pt 1):1256-61. PubMed ID: 15371818
[TBL] [Abstract][Full Text] [Related]
5. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Duh FM; Chen F; Kishida T; Glenn G; Choyke P; Scherer SW; Zhuang Z; Lubensky I; Dean M; Allikmets R; Chidambaram A; Bergerheim UR; Feltis JT; Casadevall C; Zamarron A; Bernues M; Richard S; Lips CJ; Walther MM; Tsui LC; Geil L; Orcutt ML; Stackhouse T; Lipan J; Slife L; Brauch H; Decker J; Niehans G; Hughson MD; Moch H; Storkel S; Lerman MI; Linehan WM; Zbar B
Nat Genet; 1997 May; 16(1):68-73. PubMed ID: 9140397
[TBL] [Abstract][Full Text] [Related]
6. Hereditary papillary renal cell carcinoma.
Jacoba IM; Lu Z
Semin Diagn Pathol; 2024 Jan; 41(1):28-31. PubMed ID: 38135585
[TBL] [Abstract][Full Text] [Related]
7. Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report.
Ferlicot S; Just PA; Compérat E; Rouleau E; Tissier F; Vaessen C; Richard S
Diagn Pathol; 2021 Nov; 16(1):107. PubMed ID: 34801057
[TBL] [Abstract][Full Text] [Related]
8. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
[TBL] [Abstract][Full Text] [Related]
9. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma.
Wadt KA; Gerdes AM; Hansen TV; Toft BG; Friis-Hansen L; Andersen MK
Fam Cancer; 2012 Sep; 11(3):535-7. PubMed ID: 22717761
[TBL] [Abstract][Full Text] [Related]
10. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.
Fischer J; Palmedo G; von Knobloch R; Bugert P; Prayer-Galetti T; Pagano F; Kovacs G
Oncogene; 1998 Aug; 17(6):733-9. PubMed ID: 9715275
[TBL] [Abstract][Full Text] [Related]
11. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.
Lubensky IA; Schmidt L; Zhuang Z; Weirich G; Pack S; Zambrano N; Walther MM; Choyke P; Linehan WM; Zbar B
Am J Pathol; 1999 Aug; 155(2):517-26. PubMed ID: 10433944
[TBL] [Abstract][Full Text] [Related]
12. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
Schmidt L; Junker K; Weirich G; Glenn G; Choyke P; Lubensky I; Zhuang Z; Jeffers M; Vande Woude G; Neumann H; Walther M; Linehan WM; Zbar B
Cancer Res; 1998 Apr; 58(8):1719-22. PubMed ID: 9563489
[TBL] [Abstract][Full Text] [Related]
13. Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma.
Prat E; Bernués M; Del Rey J; Camps J; Ponsa I; Algaba F; Egozcue J; Caballín MR; Gelabert A; Miró R
Cancer Genet Cytogenet; 2006 Jan; 164(2):142-7. PubMed ID: 16434318
[TBL] [Abstract][Full Text] [Related]
14. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
15. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
[TBL] [Abstract][Full Text] [Related]
16. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
[TBL] [Abstract][Full Text] [Related]
17. Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Sebai M; Tulasne D; Caputo SM; Verkarre V; Fernandes M; Guérin C; Reinhart F; Adams S; Maugard C; Caron O; Guillaud-Bataille M; Berthet P; Bignon YJ; Bressac-de Paillerets B; Burnichon N; Chiesa J; Giraud S; Lejeune S; Limacher JM; de Pauw A; Stoppa-Lyonnet D; Zattara-Cannoni H; Deveaux S; Lidereau R; Richard S; Rouleau E
Hum Mutat; 2022 Mar; 43(3):316-327. PubMed ID: 34882875
[TBL] [Abstract][Full Text] [Related]
18. Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations.
Li S; Shuch BM; Gerstein MB
PLoS Genet; 2017 Mar; 13(3):e1006685. PubMed ID: 28358873
[TBL] [Abstract][Full Text] [Related]
19. The genetic basis of cancer of the kidney.
Linehan WM; Walther MM; Zbar B
J Urol; 2003 Dec; 170(6 Pt 1):2163-72. PubMed ID: 14634372
[TBL] [Abstract][Full Text] [Related]
20. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
